FDA grants accelerated approval to Ultragenyx's GENGLYCOS for GSDIa
Ultragenyx won accelerated FDA approval on 19 August 2026 for GENGLYCOS, the first gene therapy for glycogen storage disease type Ia, in patients 8 and older without AAV8 antibodies. The wholesale price is $2.7 million per patient.

What the FDA cleared
The label covers adults and children aged 8 and older with GSDIa who do not have antibodies to AAV8, the virus that carries the gene. Patients with those antibodies cannot receive the one-time infusion.
GENGLYCOS, also called DTX401 and pariglasgene brecaparvovec-opnr, is Ultragenyx's first gene therapy approval and its fifth FDA approval overall. The agency granted a Priority Review Voucher with the decision. The therapy is liver-directed: it aims to let the liver break down glycogen and produce glucose during fasting or metabolic stress, the company said.
Eric Crombez, Ultragenyx's chief medical officer, said the approval fulfills the company's commitment to provide the first therapy that directly targets the root cause of GSDIa.
The cornstarch burden
GSDIa is caused by a deficiency of the enzyme that releases glucose from the liver into the bloodstream. Patients rely on raw cornstarch every three to four hours, including overnight, to avoid life-threatening hypoglycemia. The disease affects 1,500 to 2,500 patients in the US and 6,000 to 8,000 worldwide in commercially accessible geographies.
Glucose control with cornstarch is crude, with large swings, and patients end up spending a large fraction of the day significantly hyperglycemic to avoid hypoglycemic episodes, according to Ultragenyx. The company says the therapy is designed to reduce dependence on frequent cornstarch dosing.
"Any missed cornstarch puts patients at risk of severe hypoglycemia, seizures, and even death," David Weinstein, a GSDIa specialist, said in Ultragenyx's announcement.
The trial behind the approval
The Phase 3 GlucoGene study was randomized, double-blind and placebo-controlled, and enrolled 46 patients aged 8 and older for 48 weeks. At 48 weeks, the GENGLYCOS arm had a 31% larger decrease in cornstarch requirements than placebo (P < .001). It also recorded one fewer cornstarch dose per day than placebo. Ultragenyx said the trial met its primary endpoint while maintaining glycemic control.
Surrogate endpoint and safety
The FDA decided late in its review to accept reduced cornstarch use as a surrogate endpoint, which is why the approval is accelerated. Ultragenyx will need to generate additional evidence showing that the reduction is associated with clinical benefit and improved fasting tolerance over time.
Serious adverse events in the two clinical studies included anaphylaxis, adrenal insufficiency, high lactate levels and hypoglycemia. Hypertriglyceridemia was more common with GENGLYCOS than placebo, at 29% versus 8%.
Weinstein said he expects prevention of severe hypoglycemia to be the key benefit after treatment.
Price, launch and next steps
Ultragenyx said at approval that it expected a US launch within 30 to 60 days and had treatment centers and commercial inventory in place. It delayed revenue guidance until it gains more visibility into reimbursement and market demand. The wholesale price is $2.7 million per patient, for a one-time treatment.
Under the accelerated approval, Ultragenyx has agreed to supply two years of safety and efficacy data from open-label commercial treatment of 50 patients and 20 control patients who cannot receive GENGLYCOS because of anti-AAV8 antibodies. The control group will be followed through the company's GSDIa Disease Monitoring Program, which will track trial participants and commercial patients for up to 10 years.
Weinstein said patients often consume well over 1,000 calories a day from cornstarch, and many lost weight after treatment. He also said only eight years of follow-up exist so far, and that the kidneys carry the same enzyme defect, so long-term monitoring matters.
Sources
20- 01Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene TherapyEN
- 02Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen StorEN
- 03Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen StorEN
- 04FDA approves first gene therapy to treat glycogen storage disease type IaEN
- 05Gene Therapy Pioneers Win 2026 Breakthrough Prize - The ScientistEN
- 06Breakthrough Prizes honor gene therapy restoring sight and frontier physics, math - ChosunbizEN
- 07UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapyEN
- 08Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVI™ to TEN
- 09Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)EN
- 10STAT+: Gene therapy’s long-debated cancer risk materializesEN
- 11 Anthropic skips six-year waitlist with massive $3.4 billion gas turbine generator deal EN
- 12Coinbase receives approval to become a chartered trust bankEN
- 13AI chatbots aren’t therapists. But can they finally get men to open up?EN
- 14Scientists wipe out deadly brain tumors in every mouse tested with new cancer therapyEN
- 15#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be trickyEN
- 16MucoLife Therapeutics secures €91K from Vinnova to scale manufacturing of COPD treatmentEN
- 17Gene editing could replace a lifetime of medication, but there's a catchEN
- 18China touts AI milestone: models generate more tokens than used in trainingEN
- 19Seven new tumor cases reported among patients on Novartis' Zolgensma gene therapyEN
- 20AC Milan, Inter strike ‘€650m’ Generali naming rights deal for new stadiumEN
All figures and quotations in this text come from the sources listed below.
Content prepared by the editorial team with AI assistance.
Comments
0- No comments yet — be the first.